Logo

Horizon Presents Results of Uplizna (inebilizumab-cdon) in N-MOmentum Trial for NMOSD at AAN 2021

Share this

Horizon Presents Results of Uplizna (inebilizumab-cdon) in N-MOmentum Trial for NMOSD at AAN 2021

Shots:

  • The company reported the data from the N-MOmentum trial involves assessing Uplizna in patients with NMOSD
  • The results from the N-MOmentum trial demonstrated a reduction in pain- long-term safety- and efficacy outcomes. Additional results from the new survey demonstrated NMOSD patient attitudes towards diagnosis and treatment
  • Uplizna is the first FDA-approved B-cell depleter to treat adult patients with AQP4 antibody-positive NMOSD

  Ref: Horizon | Image: Horizon

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions